Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma.

about

Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma.

Item

http://www.wikidata.org/entity/Q49537835

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Dosimetric advantages and clin ...... anal squamous cell carcinoma.

@en

Dosimetric advantages and clin ...... anal squamous cell carcinoma.

@nl

type

Item

label

Dosimetric advantages and clin ...... anal squamous cell carcinoma.

@en

Dosimetric advantages and clin ...... anal squamous cell carcinoma.

@nl

prefLabel

Dosimetric advantages and clin ...... anal squamous cell carcinoma.

@en

Dosimetric advantages and clin ...... anal squamous cell carcinoma.

@nl

P1476

Dosimetric advantages and clin ...... anal squamous cell carcinoma.

@en

P2093

Katsuyuki Sakanaka

http://www.w3.org/2001/XMLSchema#string

Kota Fujii

http://www.w3.org/2001/XMLSchema#string

Masahiro Hiraoka

http://www.w3.org/2001/XMLSchema#string

Satoshi Itasaka

http://www.w3.org/2001/XMLSchema#string

Takahiro Horimatsu

http://www.w3.org/2001/XMLSchema#string

Takashi Mizowaki

http://www.w3.org/2001/XMLSchema#string

Yoshiharu Sakai

http://www.w3.org/2001/XMLSchema#string

Yuichi Ishida

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.

Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.

Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis.

Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.

Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.

Plan comparison of volumetric-modulated arc therapy (RapidArc) and conventional intensity-modulated radiation therapy (IMRT) in anal canal cancer.

RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal

Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas.

Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: A retrospective review from a large academic center.

Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.

P304

368-379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3857/ROJ.2017.00227

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28893059

http://www.w3.org/2001/XMLSchema#string

P932

5769885

http://www.w3.org/2001/XMLSchema#string